BiotechTube

Patritumab Deruxtecan

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malignant Neoplasm

Conditions

Malignant Neoplasm

Trial Timeline

May 26, 2025 → Dec 30, 2030

NCT ID
NCT06941272

About Patritumab Deruxtecan

Patritumab Deruxtecan is a phase 1/2 stage product being developed by Daiichi Sankyo for Malignant Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06941272. Target conditions include Malignant Neoplasm.

What happened to similar drugs?

5 of 20 similar drugs in Malignant Neoplasm were approved

Approved (5) Terminated (2) Active (13)
✅Deep Neuromuscular Blockade (NMB) + Moderate Neuromuscular Blockade (NMB) + Sugammadex + NeostigmineMerckApproved
✅Rocuronium + Sugammadex + Neostigmine + GlycopyrrolateMerckApproved
✅ZelborafRocheApproved
✅Atezolizumab Injection [Tecentriq]RocheApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT05620914Phase 2Withdrawn
NCT06941272Phase 1/2Recruiting
NCT06596694Phase 1/2Recruiting
NCT05865990Phase 2Active
NCT04479436Phase 2Terminated
NCT02980341Phase 1/2Completed

Competing Products

20 competing products in Malignant Neoplasm

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
39
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Tadalafil + GemcitabineEli LillyPhase 1
29
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
32
DS-1123Daiichi SankyoPhase 1
29
DS-8201aDaiichi SankyoPhase 1
29
DS-5573aDaiichi SankyoPhase 1
21
DS-6051bDaiichi SankyoPhase 1
29
U3-1565Daiichi SankyoPhase 1
29
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
39
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
29
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
CP-461Astellas PharmaPhase 2
27
enfortumab vedotinAstellas PharmaPhase 1
29
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
36
Perampanel + Standard of CareEisaiPhase 1/2
32
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
40
Eribulin MesylateEisaiPhase 1
29